201 related articles for article (PubMed ID: 27845909)
1. Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.
Ekpe-Adewuyi E; Lopez-Campistrous A; Tang X; Brindley DN; McMullen TP
Oncotarget; 2016 Dec; 7(50):83684-83700. PubMed ID: 27845909
[TBL] [Abstract][Full Text] [Related]
2. PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer.
Lopez-Campistrous A; Adewuyi EE; Benesch MGK; Ko YM; Lai R; Thiesen A; Dewald J; Wang P; Chu K; Ghosh S; Williams DC; Vos LJ; Brindley DN; McMullen TPW
EBioMedicine; 2016 Oct; 12():86-97. PubMed ID: 27682510
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer.
Zhang J; Wang P; Dykstra M; Gelebart P; Williams D; Ingham R; Adewuyi EE; Lai R; McMullen T
J Pathol; 2012 Oct; 228(2):241-50. PubMed ID: 22744707
[TBL] [Abstract][Full Text] [Related]
4. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways.
Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P
Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956
[TBL] [Abstract][Full Text] [Related]
5. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.
Han J; Zhang M; Nie C; Jia J; Wang F; Yu J; Bi W; Liu B; Sheng R; He G; Kong L; Zheng L; Pang R; Ding Z; Chen L; Guan Q; Pan S; Meng X; Xu J; Liu L; Zhang J
Cell Death Dis; 2019 Feb; 10(3):195. PubMed ID: 30814512
[TBL] [Abstract][Full Text] [Related]
6. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological progression by directly targeting SOX11 and regulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways.
Wang Y; Liu BG; Zhou CX
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5863-5873. PubMed ID: 31298337
[TBL] [Abstract][Full Text] [Related]
8. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
[TBL] [Abstract][Full Text] [Related]
9. miRNA‑148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways.
Xu Y; Han YF; Zhu SJ; Dong JD; Ye B
Oncol Rep; 2017 Nov; 38(5):3085-3093. PubMed ID: 28901486
[TBL] [Abstract][Full Text] [Related]
10. Autocrine activation of platelet-derived growth factor receptor α in metastatic papillary thyroid cancer.
Adewuyi EE; Deschenes J; Lopez-Campistrous A; Kattar MM; Ghosh S; McMullen TPW
Hum Pathol; 2018 May; 75():146-153. PubMed ID: 29408504
[TBL] [Abstract][Full Text] [Related]
11. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.
Dultz LA; Dhar S; Ogilvie JB; Heller KS; Bar-Sagi D; Patel KN
Surgery; 2013 Dec; 154(6):1239-44; discussion 1244-5. PubMed ID: 24094449
[TBL] [Abstract][Full Text] [Related]
12. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
13. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.
Govaere O; Petz M; Wouters J; Vandewynckel YP; Scott EJ; Topal B; Nevens F; Verslype C; Anstee QM; Van Vlierberghe H; Mikulits W; Roskams T
Oncogene; 2017 Nov; 36(47):6605-6616. PubMed ID: 28783171
[TBL] [Abstract][Full Text] [Related]
14. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.
He J; Jin Y; Zhou M; Li X; Chen W; Wang Y; Gu S; Cao Y; Chu C; Liu X; Zou Q
Cancer Sci; 2018 Mar; 109(3):642-655. PubMed ID: 29274137
[TBL] [Abstract][Full Text] [Related]
15. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
16. CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial-mesenchymal transition.
Shu C; Wang S; Hu J; Xu M; Deng H; Maimaiti Y; Huang T
J Endocrinol Invest; 2023 Mar; 46(3):545-557. PubMed ID: 36306106
[TBL] [Abstract][Full Text] [Related]
17. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.
Yang QL; Zhang LY; Wang HF; Li Y; Wang YY; Chen TT; Dai MF; Wu HH; Chen SL; Wang WR; Wu Q; Chen CJ; Zhou CZ
Oncotarget; 2017 Jun; 8(23):37448-37463. PubMed ID: 28415580
[TBL] [Abstract][Full Text] [Related]
18. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways.
Cheng SP; Yin PH; Hsu YC; Chang YC; Huang SY; Lee JJ; Chi CW
Oncol Rep; 2011 Nov; 26(5):1265-71. PubMed ID: 21750869
[TBL] [Abstract][Full Text] [Related]
19. HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway.
Wang SC; Chai DS; Chen CB; Wang ZY; Wang L
Biomed Pharmacother; 2015 Oct; 75():33-9. PubMed ID: 26463629
[TBL] [Abstract][Full Text] [Related]
20. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]